Document 0624
 DOCN  M9650624
 TI    Carnitine in human immunodeficiency virus type 1 infection/acquired
       immune deficiency syndrome.
 DT    9605
 AU    Mintz M; University of Medicine and Dentistry of New Jersey-Robert Wood;
       Johnson Medical School at Camden 08103, USA.
 SO    J Child Neurol. 1995 Nov;10 Suppl 2:S40-4. Unique Identifier : AIDSLINE
       MED/96155690
 AB    There is an increasing body of evidence that subgroups of patients
       infected with human immunodeficiency virus type 1 possess carnitine
       deficiency. Secondary carnitine deficiencies in these individuals may
       result from nutritional deficiencies, gastrointestinal disturbances,
       renal losses, or shifts in metabolic pathways. However, tissue depletion
       precipitated by drug toxicities, particularly zidovudine, is a major
       etiology and concern. Carnitine deficiency may impact on energy and
       lipid metabolism, causing mitochondrial and immune dysfunction. There
       are convincing laboratory data showing the in vitro ameliorative effects
       of L-carnitine supplementation of zidovudine-induced myopathies and
       lymphocyte function. Studies measuring the impact of L-carnitine
       supplementation on clinical characteristics are ongoing.
 DE    Carnitine/*METABOLISM  Human  HIV Infections/*METABOLISM  *HIV-1
       Vitamin B Deficiency/*METABOLISM  JOURNAL ARTICLE  REVIEW  REVIEW,
       TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).